ClinicalTrials.gg
Not yet recruitingNCT07947862Updated Nov 19, 2026

Interleukin 6 Versus Lactic Acid in Septic Shock

An interventional study of Assessment of IL-6 and Biochemical Assessment in Septic Shock, sponsored by New Valley University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by New Valley University · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The aim of this study is to compare between IL 6 versus lactate level for early prediction and prognosis over the first two days or 48 hours of ICU stay in patients with septic shock.

02

Conditions studied

  • Septic Shock

Browse trials for

03

In context

Shock, Septic

1,082 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.

This study's planned enrollment of 2 is below the median of 80 across 636 interventional studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

New Valley University is the lead sponsor of 26 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:• Adult patients aged ≥18 years.

  • Both sexes.
  • Admitted to the ICU with a diagnosis of sepsis according to Sepsis-3 criteria.
  • Presence of life-threatening organ dysfunction indicated by an increase in SOFA score of ≥ 2 points from baseline.

Exclusion Criteria:• Pregnancy.

  • Known terminal illness with expected survival rate \< 24 hours.
  • Cardiopulmonary resuscitation (CPR) within 24 hours before ICU admission.
  • Chronic kidney disease requiring analysis.
  • LAC next ≥ LAC peak; Patients' medical records are insufficient.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
2 participants (estimated)

Study arms

  • Experimental
    Assessment of IL-6

    The patients will have blood drawn on day 1 and day 2 of their stay in the ICU. The samples will be processed immediately;

    Diagnostic Test: Assessment of IL-6

  • Experimental
    Biochemical Assessment

    Fasting blood samples will be drawn from ICU patients by venepuncture after the hemodynamic stabilization phase of admission and after 2 days of being in the ICU to measure renal function (ions and creatinine), liver function (bilirubin), nutritional parameters (folic acid, B12 and copper), hematimetric \[hemoglobin, leukocytes, platelets, INR and activated partial thromboplastin time (APTT)\] and inflammatory parameters \[lactic acid, fibrinogen, lactate dehydrogenase (LDH)\].

    Diagnostic Test: Biochemical Assessment

Interventions

  • Diagnostic testAssessment of IL-6

    they will be centrifuged at 3500 rpm for 10 min at 4 ◦C and frozen at -80 ◦C..

  • Diagnostic testBiochemical Assessment

    Fasting blood samples will be drawn from ICU patients by venepuncture after the hemodynamic stabilization phase of admission and after 2 days of being in the ICU to measure renal function (ions and creatinine), liver function (bilirubin), nutritional parameters (folic acid, B12 and copper), hematimetric \[hemoglobin, leukocytes, platelets, INR and activated partial thromboplastin time (APTT)\] and inflammatory parameters \[lactic acid, fibrinogen, lactate dehydrogenase (LDH)\]. PCR and PCT will be performed by the hospital laboratory using standard techniques.

06

What researchers measure

Primary outcomes

  1. • Correlation between IL-6 and lactic acid.

    Time frame: 90 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2027, 2 months later.

Of 164 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 2 months is below that.

Counting every sponsor, half of 172 studies reached it within 25 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947862
Lead sponsor
New Valley University
Responsible party
Ahmed Ismail Abdelsabour (lecture, New Valley University) — Principal investigator
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion